Atypical antipsychotics and metabolic syndrome;Atypische neuroleptika und metabolisches syndrom

Wiener Medizinische Wochenschrift

Volumn 157, Issue 11-12, 2007, Pages 255-270

  Baranyi, Andreas ^a   Yazdani, Renè ^a   Haas Krammer, Alexandra ^a   Stepan, Alexandra ^a   Kapfhammer, Hans Peter ^a   Rothenhäusler, Hans Bernd ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atypical antipsychotics; Hyperlipidemia; Metabolic abnormalities; New onset typ 2 diabetes; Weight gain

Indexed keywords

ADIPONECTIN; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOKINE; FLUPHENAZINE; GHRELIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HYDROCORTISONE; LEPTIN; OLANZAPINE; PROOPIOMELANOCORTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ZIPRASIDONE;

CARBOHYDRATE METABOLISM; ENDOCRINE DISEASE; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PSYCHOSIS; REVIEW; SCREENING; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CARBOHYDRATE METABOLISM; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RATS; RISK FACTORS; TIME FACTORS; WEIGHT GAIN;

EID: 34347358687     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0379-9     Document Type: Review

References (75)

1. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al (2005) Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54: 862-871
2. Allison DB, Fontaine KR, Manson JE, Stevens J, Vanitallie TB (1999) Annual deaths attributable to obesity in the United States. JAMA27 282: 1530-1538
3. Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT (2001) Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry 62: 694-700
4. Kraepelin E (1915) Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. Achte, vollständig umgearbeitete Auflage. IV. Band. Klinische Psychiatric III. Teil. Barth Verlag, Leipzig
5. Bleuler E (1911) Dementia Praecox oder die Gruppe der Schizophrenien. Deuticke, Leipzig Wien
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al (2005) Diagnosis and management of the metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735-2752
7. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM et al (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66: 1116-1121
8. Rothenhäusler HB, Kapfhammer HP (2005) Psychopharmacotherapy in somatic diseases - treatment principles in daily medical routine. Wien Med Wochenschr 155: 303-314. Review
9. Schwartz TL, Nihaani N, Jindal S, Virk S, Jones N (2004) Psychiatric medication-induced obesity: a review. Obesity reviews 5: 115-121
10. Simpson GM (2005) Atypical antipsychotics and the burden of disease. Am J Manag Care 11(8 Suppl): 235-241
11. Leucht S, Wagenpfeil S, Hamann J, Kissling W (2004) Amisulpride is an "atypical" antipsychotic associated with low weight gain. Psychopharmacology (Berl) 173: 112-115
12. Centorrino F, Fogarty KV, Cimbolli P, Salvatore P, Thompson TA, Sani G et al (2005) Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 11: 241-247
13. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B et al (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obes Res 14: 36-51
14. Lebovitz HE (2001) Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 62 (Suppl 27): 5-9
15. Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD (2005) Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 19 (Suppl 6): 110-117
16. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, Haloperidol, or Risperidone. J Clin Psychiatry 62: 231-238
17. Umbricht DSG, Pollack S, Kane JM (1994) Clozapine and weight gain. J Clin Psychiatry 55 (9 Suppl B): 157-160
18. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159: 1055-1057
19. Frankenburger FM, Zanarini MC, Kando J et al (1998) Clozapine and body mass change. Biol Psychiatry 43: 520-524
20. Consensus Meeting, Schizophrenia and Diabetes 2003, Dublin (2004) British Journal of Psychiatry 184 (Suppl 47): 112-114
21. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002) Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63: 920-930
22. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856-865
23. Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C et al (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 65: 557-564
24. Bishop JR, Ellingrod VL, Moline J, Miller D (2006) Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to Olanzapine or Olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 12: 47-50
25. Baptista T, Kin NM, Beaulieu, de Baptista EA (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35(6): 205-19
26. Correll CU, Malhotra AK (2004) Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 174: 477-489
27. Kishi T, Horiguchi J (2003) Psychiatric disorders and neuronal mechanisms underlying energy intake and expenditure: a review. Nihon Shinkei Seishin Yakuriaku Zasshi 23: 197-203
28. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, Koyama T (2005) Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30: 106-110
29. Baptista T, Beaulieu S (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 47: 742-749
30. Clement K, Vaisse C, Lahou N, Cabrol S, Pelloux V, Casssuto D et al (1998) A mutation in the leptin receptor genes causes obesity and pituarity dysfunction. Nature 392: 398-401
31. Montague CT, Faroogi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al (1997) Congenital leptin deficiency is associated with severe early- onset obesity in humans. Nature 387: 903-907
32. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL (2002) Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 8: 2391-2394
33. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M (2002) Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol 22: 424-426
34. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW (2005) Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmagology 30: 184-191
35. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623-1630
36. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K (2005) Correlations of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68 (Suppl 1): 60-64
37. Ryan MC, Shrifi N, Condren R, Thakore JH (2004) Evidence of basal pituarity-adrenal overactivity in first episode, drug native patients with schizophrenia. Psychoneuroendocrinology 29: 1065-1070
38. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y et al (2006) Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20: 75-79
39. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al (2001) The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946
40. Haak M, Hinze Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T (1999) Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33: 407-418
41. Hinze-Selch D, Schuld A, Kraus D, Kuhn M, Uhr M, Haak M, Pollmacher T (2000) Effects of antidepressants on weight and on the plasma levels of leptin, TNF-Alpha and soluble TNF receptors: a longitudinal study in patients treated with amitryptilin or paroxetine. Neuropsychopharmacology 23: 13-19
42. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T (2002) Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35: 220-225
43. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl 7): 4-18
44. Barnas C, Hummer M, Kapfhammer HP, Lechleitner M, Ludvik M (2005) Medical Update Psychiatrie/Schizophrenie: Antipsychotische Therapie und Diabetes Risiko. (2. Auflage). Update - Internationale Zeitschrift für ärztliche Fortbildung Nr. 40
45. Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychosis. J Clin Psychiatry 61: 742-749
46. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M et al (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158: 1719-1722
47. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160: 1396-1404
48. Soholm B, Lublin H (2003) Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand 107: 344-350
49. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB (2005) Effect of olanzapin on body composition and energy expentidure in adults with first-episode psychosis. Am J Psychiatry 162: 118-123
50. Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H et al (2005) Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 38: 206-213
51. Mc Kee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP (2005) Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. J Clin Psychiatry 66: 1161-1168
52. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP et al (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187: 537-543
53. Masi G, Milone A, Canepa G, Millepiedi S, Mucci M, Muratori F (2006) Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 21: 51-57
54. Cohen S, Glazewski R, Khan S, Khan A (2001) Weight gain with risperidone among patients with mental retardation: effect of caloric restriction. J Clin Psychiatry 62: 114-116
55. Ganguli R, Brar JS, Ayrton Z (2001) Weight gain over 4 months in schizophrenia patients: a comparison of Olanzapine and risperidone. Schizophr Res 49: 261-267
56. Barak Y (2002) No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 63: 117-119
57. Martin A, Scabill L, Anderson GM, Aman M, Arnold LE, Mc Cracken JT et al (2004) Weight and leptin changes among risperidone-treated youths with autism: 6 month prospective data. Am J Psychiatry 161: 1125-1127
58. Papadimitriou GN, Theleritis CG, Dikeos DG, Psarros CJ, Soldatos CR (2006) Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenicpatient. Int Clin Psychopharmacol 21: 181-184
59. Mortimer A, Martin S, Loo H, Peuskens J; Solianol Study Group (2004) A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 19: 63-69
60. Patel NC, Kistler JS, James EB, Crismon ML (2004) A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 24: 824-830
61. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G et al (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63: 992-997
62. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM (2001) The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62: 347-349
63. Arato M, O'Connor R, Meltzer HY (2002) A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone extended use in Schizophrenia (Zeus) study. Int Clin Psychopharmacol 17: 207-215
64. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A (2003) Weight, lipids, glucose and behavioural measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 64: 60-62
65. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K (2003) Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160: 741-748
66. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771
67. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690
68. Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14: 455-463
69. Mc Quade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S et al (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (Suppl 18): 47-56
70. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66: 49-51
71. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. Am J Psychiatry 157: 975-981
72. Theisen FM, Gebhardt S, Brömel T, Otto B, Heldwein W, Heinzel-Guttenbrunner M et al (2005) A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 112: 1411-1416
73. Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M et al (2004) Serum ghrelin concentration in patients receiving olanzapine or risperidone. Psychopharmacology 172: 230-232
74. Himmerich H, Fulda S, Kunzel HE, Pfennig A, Dzaja A, Cummings DE, Pollmacher T (2005) Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 52: 11-16
75. Birkas Kovats D, Palik E, Faludi G, Cseh K (2005) Possible connection between ghrelin, resistin and TFA-alpha levels and the metabolic syndrome caused by atypical antipsychotics Neuropsychopharmacol Hung 7: 132-139